KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Net Cash Flow (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Net Cash Flow data on record, last reported at $11.4 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 63.1% year-over-year to $11.4 million; the TTM value through Dec 2025 reached -$118.2 million, down 195.69%, while the annual FY2025 figure was -$118.2 million, 195.69% down from the prior year.
  • Net Cash Flow reached $11.4 million in Q4 2025 per PCRX's latest filing, up from -$153.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $451.5 million in Q4 2021 and bottomed at -$358.8 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $2.9 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1885.67% in 2021, then plummeted 13965.07% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $451.5 million in 2021, then plummeted by 101.17% to -$5.3 million in 2022, then surged by 1125.15% to $54.2 million in 2023, then crashed by 43.13% to $30.8 million in 2024, then crashed by 63.1% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $11.4 million in Q4 2025, -$153.0 million in Q3 2025, and $16.7 million in Q2 2025.